Deferiprone is NOT indicated for myelofibrosis
Deferiprone is specifically contraindicated for use in myelofibrosis patients. The FDA-approved indication for deferiprone is limited to transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate 1. The drug label explicitly states that "safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome" 1, and this limitation extends to myelofibrosis.
Why Deferiprone Should Be Avoided in Myelofibrosis
Critical Safety Concern: Agranulocytosis Risk
The primary reason deferiprone is not used in myelofibrosis relates to its serious hematologic toxicity profile. Deferiprone carries a black box warning for agranulocytosis (severe neutropenia), occurring in approximately 1% of patients 2. This risk is particularly problematic in myelofibrosis patients who:
- Already have baseline cytopenias as part of their disease
- Are at increased risk for infections due to their underlying condition
- May be receiving other myelosuppressive therapies
Research data confirm this concern: a Dutch multicenter trial found that deferiprone was "clearly not effective" in patients with myelofibrosis, and one patient with myelodysplasia developed agranulocytosis after 12 months of treatment 3. The study concluded that deferiprone should only be used in well-controlled clinical trials due to safety concerns.
Guideline Recommendations for Iron Chelation
When myelofibrosis patients develop transfusional iron overload, the recommended iron chelators are:
First-line options:
- Deferoxamine (subcutaneous administration)
- Deferasirox (oral, once daily)
These recommendations come from NCCN and ESMO guidelines for myelodysplastic syndromes, which share similar transfusion-dependent characteristics with myelofibrosis 4, 5, 6. The guidelines specifically note that deferiprone is "licensed in Europe for the treatment of iron overload in patients with β-thalassemia when deferoxamine is inadequate or contraindicated" 4 - not for myeloid malignancies.
When to Consider Iron Chelation in Myelofibrosis
If your myelofibrosis patient requires iron chelation, consider it when:
- Serum ferritin >2500 ng/mL
- Patient has received >20 RBC transfusions
- Ongoing transfusions are anticipated
- Patient is a candidate for allogeneic stem cell transplantation (chelate early, as even moderate iron overload increases transplant-related mortality) 5
Use deferasirox or deferoxamine, NOT deferiprone 4, 6.
Common Pitfall to Avoid
Do not extrapolate the thalassemia indication to myelofibrosis simply because both conditions involve transfusional iron overload. The underlying bone marrow pathology and baseline cytopenia risk in myelofibrosis make deferiprone's neutropenia risk unacceptable in this population.